Spondyloarthritis & psoriatic arthritis
Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis
Authors' conclusion
In PsA, BD-2 at baseline is quantitatively associated with clinical response to secukinumab. Patients with high levels of BD-2 at baseline reach and sustain higher rates of clinical response after treatment with secukinumab.
Study context
- Population
- Patients with PsA in placebo-controlled phase III trials of secukinumab; separate trial of PsA patients treated with secukinumab or adalimumabnearly 2000 (discovery)
- Comparison
- Baseline serum BD-2 levels vs clinical response to secukinumab, placebo or adalimumab
- Outcome
- Association of baseline serum biomarkers with clinical response (eg, ACR20, ACR50, ACR70)
Methodological detailssecondary analysis of placebo-controlled phase III trials, proteomics, statistical learning with controlled feature selection, ELISA validation, independent validation cohorts
- Secondary analysis of placebo-controlled phase III trials
- Proteomics
- Statistical learning with controlled feature selection
- ELISA validation
- Independent validation cohorts
Performance
As reported in the abstract
- Baseline BD-2 robustly associated with clinical response (eg, ACR20, ACR50, ACR70) to secukinumab, but not to placebo
- Finding validated in two independent clinical studies not used for discovery
- Predictivity of BD-2 independent of baseline PASI
Further findings
Time course of BD-2 association with secukinumab response · 4 to 52 weeks
- Association observed as early as 4 weeks and maintained up to 52 weeks
BD-2 and response to adalimumab
- BD-2 also predicted response to adalimumab
BD-2 and response to secukinumab in RA
- BD-2 not predictive of response to secukinumab in RA
Original publication
Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis. RMD Open. Published 15 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →